<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019755</url>
  </required_header>
  <id_info>
    <org_study_id>IN_JSI_103</org_study_id>
    <nct_id>NCT05019755</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 2-way Crossover Clinical Trial to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of food on the pharmacokinetics of IN-A002 capsule&#xD;
      in healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the effect of High-fat diet on the pharmacokinetics of single dose of IN-A002&#xD;
      capsule in healthy male subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">February 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of IN-A002(IN-115314)</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite ratio of IN-116118(primary metabolite of IN-A002(IN-115314))</measure>
    <time_frame>up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A(First period) to B(Second period) order</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: Oral Administration of IN-A002(IN-115314) in fasting status&#xD;
B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet&#xD;
There will be a wash out period of 7days between period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(First period) to A(Second period) order</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: Oral Administration of IN-A002(IN-115314), 30 minutes after high-fat diet&#xD;
A: Oral Administration of IN-A002(IN-115314) in fasting status&#xD;
There will be a wash out period of 7days between period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-A002(IN-115314) capsule</intervention_name>
    <description>Oral Administration of IN-A002(IN-115314), single dose</description>
    <arm_group_label>A(First period) to B(Second period) order</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-A002(IN-115314) capsule</intervention_name>
    <description>Oral Administration of IN-A002(IN-115314), single dose</description>
    <arm_group_label>B(First period) to A(Second period) order</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male adults aged 19 to 55 years (inclusive) at the time of signing the&#xD;
             informed consent form.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m^2 with a body weight ≥ 50.0 kg and ≤ 90.0&#xD;
             kg at screening. BMI (kg/m^2) = Weight(kg) / {Height(m)}^2&#xD;
&#xD;
          -  Decides to participate voluntarily in the study after being fully informed of and&#xD;
             understanding the study completely, and provides his written informed consent prior to&#xD;
             screening procedure.&#xD;
&#xD;
          -  Determined eligible for this study in the opinion of the investigator based on the&#xD;
             results of vital signs, physical examination, 12-lead electrocardiogram, clinical&#xD;
             laboratory tests, and medical interview.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history or current evidence of clinically significant disorder of hepatic,&#xD;
             renal, nervous, respiratory, endocrine, hemato-oncologic, cardiovascular, urinary,&#xD;
             and/or psychiatric system.&#xD;
&#xD;
          -  Has a history or current evidence of gastrointestinal disease that may affect the&#xD;
             safety and Pharmacokinetics assessment of investigational product(IP) or a history of&#xD;
             gastrointestinal surgery (except for simple appendectomy or herniotomy).&#xD;
&#xD;
          -  Has rheumatoid arthritis or has a history.&#xD;
&#xD;
          -  Has symptomatic herpes simplex or herpes zoster or has a history within 3 months prior&#xD;
             to the scheduled first dose.&#xD;
&#xD;
          -  Has live vaccine dose within 3 months prior to the scheduled first dose or expects to&#xD;
             receive live vaccine during the clinical trial period.&#xD;
&#xD;
          -  Has a history or current evidence of clinically significant hypersensitivity to drugs&#xD;
             containing any ingredient of Janus kinase inhibitor and other drugs.&#xD;
&#xD;
          -  Has a positive result on serology tests (for hepatitis B, hepatitis C and human&#xD;
             immunodeficiency virus [HIV], syphilis) during screening test.&#xD;
&#xD;
          -  Has abnormalities one or more of the following during screening test: AST [GOT] or ALT&#xD;
             [GPT] &gt; 1.5 X upper limit of normal (ULN), Creatinine &gt; upper limit of normal (ULN),&#xD;
             ANC &lt; 2,000/uL, Hb &lt; 12.5 g/dL, Platelet &lt; 150,000/uL, QTc interval at 12-lead&#xD;
             electrocardiogram &gt; 450 msec&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure (DBP)&#xD;
             &lt; 50 mmHg or &gt; 95 mm Hg, or pulse rate (PR) &lt; 45 beats/ min or &gt; 100 beats/min on&#xD;
             vital signs measured in sitting position after taking a rest for at least 5 minutes&#xD;
             during screening test.&#xD;
&#xD;
          -  Has a history of drug abuse or has a positive response to drug abuse on urine drug&#xD;
             screening test.&#xD;
&#xD;
          -  Has taken any prescription drugs or herbal medicine within 2 weeks prior to the&#xD;
             expected date of first dose, or any over-the-counter (OTC) drug, health functional&#xD;
             food or vitamin preparation within 1 week prior to the scheduled first dose (However,&#xD;
             can participate in the study if otherwise eligible in the judgment of the&#xD;
             investigator) or is expected to take such medication during the study.&#xD;
&#xD;
          -  Has participated in any other clinical study, etc. and received IPs within 6 months&#xD;
             prior to the scheduled first dose.&#xD;
&#xD;
          -  Has donated whole blood within 2 months prior to the scheduled first dose, or has&#xD;
             donated blood components or received transfusion within a month prior to the scheduled&#xD;
             first dose.&#xD;
&#xD;
          -  Has a history of excessive smoking (&gt; 10 cigarettes/day) within 3 months prior to the&#xD;
             scheduled first dose or confirmed as positive for cotinine on urine drug screening&#xD;
             test.&#xD;
&#xD;
          -  Excessive caffeine intake (&gt; 5 units/day) or continued use of alcohol (&gt; 21&#xD;
             units/week, 1 unit = 10 g of pure alcohol).&#xD;
&#xD;
          -  Unable to stop drinking within 24 hrs prior to the scheduled first dose to post study&#xD;
             visit.&#xD;
&#xD;
          -  Unable to avoid caffeine-containing foods (e.g., coffee, tea [black tea, green tea,&#xD;
             etc.], soda, coffee-flavored milk, and nutritive tonic drink, etc.) and foods&#xD;
             containing grapefruit during each period from 24 hrs before hospitalization to&#xD;
             discharge.&#xD;
&#xD;
          -  Unable to use a medically acceptable contraceptive method stated below and does not&#xD;
             agree not to donate sperm from the scheduled first dose to 90 days after the last&#xD;
             dose.&#xD;
&#xD;
               1. Use of intrauterine device with a proven birth control failure rate by the spouse&#xD;
                  (or partner)&#xD;
&#xD;
               2. Simultaneous use of (male or female) barrier method and spermicide&#xD;
&#xD;
               3. Surgical sterilization of the subject or his partner (e.g., vasectomy,&#xD;
                  salpingectomy, tubal ligation, or hysterectomy)&#xD;
&#xD;
          -  Determined ineligible for study participation by the investigator for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohyun Kim, BS</last_name>
    <phone>+82-2-6477-0225</phone>
    <email>sohyun.kim21@inno-n.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seokuee Kim, MD, PhD</last_name>
    <phone>+82-2-6477-0207</phone>
    <email>seokuee.kim@inno-n.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital, Dept. of Clinical Pharmacology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

